Loading
A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by NovoCure GmbH, now recruiting.
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC is a phase 3 interventional study registered as NCT06216301 by NovoCure GmbH, with 734 participants planned, started 2024-07-31 and due to reach its primary completion in 2028-10. Interventions recorded: NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy. Conditions listed: Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Novocure, Pembrolizumab, Immune checkpoint inhibitors.
Shares Novocure, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Novocure, Non-small-cell lung cancer.
Shares Novocure, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/